Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Peter Cerkl"'
Autor:
Karl Wurstbauer, Margit Kazil, Marco Meinschad, Raoul Pinter, Catharina De Vries, Patrick Clemens, Christof Kreuter, Tamara Hernler, Wolfgang Hitzl, Peter Cerkl, Thomas Künzler, Alexander De Vries
Publikováno v:
Radiation Oncology, Vol 17, Iss 1, Pp 1-10 (2022)
Abstract Background In radiation treatment of locally advanced non-small cell lung cancer (LA-NSCLC), ‘margins’ from internal target volumes to planning target volumes in the range of 12 to 23 mm are reported, and avoiding exposure of the contral
Externí odkaz:
https://doaj.org/article/1daf369b7dd44f4c8d2ad05912651f12
Autor:
Otto C Burghuber, Klaus Kirchbacher, Andrea Mohn-Staudner, Maximilian Hochmair, Marie-Kathrin Breyer, Michael Studnicka, Michael Rolf Mueller, Petra Feurstein, Andrea Schrott, Bernd Lamprecht, Josef Eckmayr, Friedrich Renner, Josef Bolitschek, Wolfgang Pohl, Peter Schenk, Peter Errhalt, Peter Cerkl, Bernhard Baumgartner, Meinhard Kneussl, Sylvia Hartl
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 14 (2020)
Objectives: The Austrian Lung Cancer Audit (ALCA) is a pilot study to evaluate clinical and organizational factors related to lung cancer care across Austria. Materials and methods: The ALCA is a prospective, observational, noninterventional cohort s
Externí odkaz:
https://doaj.org/article/73d532ae76714f8d90691f9284006e19
Autor:
Vincent Cottin, Dirk Koschel, Andreas Günther, Carlo Albera, Arata Azuma, C. Magnus Sköld, Sara Tomassetti, Philip Hormel, John L. Stauffer, Indiana Strombom, Klaus-Uwe Kirchgaessler, Toby M. Maher, PASSPORT study group, Peter Cerkl, Holger Flick, Christian Geltner, Judith Löffler-Ragg, Michael Studnicka, Elisabeth Bendstrup, Helle Dall Madsen, Saher B. Shaker, Maritta Kilpelainen, Marjukka Myllaerniemi, Minna Purokivi, Seppo Saarelainen, Emmanuel Bergot, Philippe Bonniaud, Raphael Borie, Pascal Chanez, Francis Couturaud, Claire Dromer, Frederic Gagnadoux, Anne-Sophie Gamez, Anne Gondouin, Dominique Israel-Biet, Stephane Jouneau, Romain Kessler, Francois Lebargy, Sylvain Marchand-Adam, Borsi Melloni, Jean-Marc Naccache, Christophe Pison, Gregoire Prevot, Martine Reynaud-Gaubert, Abdellatif Tazi, Dominique Valeyre, Benoit Wallaert, Jost Achenbach, Stefan Andreas, Burkhard Bewig, Reiner Bonnet, Stephan Budweiser, Ulrich Costabel, Martin Faehling, Joachim Ficker, Juergen Fisher, Sven Glaeser, Christian Grah, Christian Grohe, Martin Hetzel, Wolfgang Hohenforst-Schmidt, David Jungck, Peter Kardos, Claus Keller, Martin Kohlhaeufl, Claus Kroegel, Rainer Kruegel, Berthold Michels, Joachim Mueller-Quernheim, Claus Neurohr, Heinz-Theodor Pelzer, Michael Pfeifer, Michael Prediger, Klaus F. Rabe, Winifried Randerath, Nicolas Scheonfeld, Robert Scheubel, Jens Schreiber, Hartwig Schutte, Bernd Schoenhofer, Barbara Wagener, Tobias Welte, Michael Westhoff, Heinrike Wilkens, Hubert Wirtz, Michael Henry, Michael Keane, Anthony O'Regan, Katherine O'Reilly, Fabrizio Luppi, Sandra Nutini, Alberto Pesci, Venerino Poletti, Elisabetta Rosi, Paola Rottoli, Thomas Eagan, Durdica Kulosman, Tone Blorg Sjaheim, Karl Axel Karlsson, Magnus Sköld, Sanjay Agrawal, Kesavan Suresh Babu, Stephen Bianchi, Nazia Chaudhuri, Sophie Fletcher, Michael Gibbons, Simon Hart, Gisli Jenkins, Toby Maher, Ann Millar, Joanna Porter, Nicky Simler, Lisa Spencer, Monica Spiteri, Melissa Wickremasinghe
Publikováno v:
ERJ Open Research, Vol 4, Iss 4 (2018)
Real-world studies include a broader patient population for a longer duration than randomised controlled trials (RCTs) and can provide relevant insights for clinical practice. PASSPORT was a multicentre, prospective, post-authorisation study of patie
Externí odkaz:
https://doaj.org/article/bc7d2efc99fe4cf088e6bcb6fe363782
Autor:
Wolfgang Pohl, Thomas Klikovits, Jörg Hutter, Walter Klepetko, Yawen Dong, Peter Errhalt, Michael Studnicka, Christian Geltner, Peter Cerkl, Klaus Kirchbacher, Madeleine Arns, Mir Alireza Hoda, Barbara Machan, Josef Eckmayr, Martin Flicker, Bernhard Baumgartner
Publikováno v:
Wiener klinische Wochenschrift. 128:627-634
Background Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor originating from the pleural cavity with a strong link to previous asbestos exposure. In order to determine the demographics, diagnostics, therapeutic strategies, and prog
Autor:
Mir Alireza Hoda, Christian Geltner, Peter Cerkl, Walter Klepetko, Bernhard Baumgartner, Wolfgang Pohl, Jörg Hutter, Thomas Klikovits, Barbara Machan, Martin Flicker, Sabine Zöchbauer-Müller, Josef Eckmayr, Peter Errhalt, Karin Dieckmann, Michael Studnicka, Madeleine Arns
Publikováno v:
Wiener klinische Wochenschrift. 128:618-626
Treatment of malignant pleural mesothelioma (MPM) depends on performance status of the patient, tumor stage, and histological differentiation. Chemotherapy (CHT) can be administered as first- and second-line treatment in unresectable MPM or as neoadj
Autor:
Peter Schenk, Maximilian Hochmair, Petra Feurstein, Marie-Kathrin Breyer, Andrea Schrott, Wolfgang Pohl, Peter Errhalt, Michael Rolf Mueller, Otto C. Burghuber, Josef Eckmayr, Andrea Mohn-Staudner, Peter Cerkl, Klaus Kirchbacher, Meinhard Kneussl, Sylvia Hartl, Michael Studnicka, Bernhard Baumgartner, Friedrich Renner, Bernd Lamprecht, Josef Bolitschek
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 14 (2020)
Clinical Medicine Insights. Oncology
Clinical Medicine Insights. Oncology
Objectives: The Austrian Lung Cancer Audit (ALCA) is a pilot study to evaluate clinical and organizational factors related to lung cancer care across Austria. Materials and methods: The ALCA is a prospective, observational, noninterventional cohort s
Autor:
Maria Aigner, Katharina Grif, Gudrun Russ, Richard Greil, Ronny Beer, Gabriele Kropshofer, Mirjam Eller, Claudia Marth, David Nachbaur, Hermann Kathrein, Wolfgang Mutschlechner, Michael Girschikofsky, Cornelia Lass-Flörl, Peter Cerkl, Ingo H. Lorenz, Stefan Schmid, Stephan Eschertzhuber, Igor Theurl, Wilhelm Grander
Prospective studies addressing the clinical value of broad-range PCR using the internal transcribed spacer region (ITS) for diagnosis of microscopy-negative fungal infections in nonselected patient populations are lacking. We first assessed the diagn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac3593962c453d9e3d80a7ce639fd04a
https://europepmc.org/articles/PMC3592065/
https://europepmc.org/articles/PMC3592065/
Autor:
Alois Lang, Peter Cerkl, Michael Knauer, Martina Türtscher, Etienne Wenzl, Anton Haid, Karlheinz Ammann, Felix Offner
Publikováno v:
World Journal of Surgical Oncology, Vol 5, Iss 1, p 114 (2007)
World Journal of Surgical Oncology
World Journal of Surgical Oncology
Background Different molecular therapies like the EGFR-inhibiting antibody cetuximab have come into clinical practice. Cetuximab is EMEA-approved for metastatic colorectal cancer and advanced squamous-cell head and neck cancer. Administration is said